ResMed Inc. (NYSE:RMD) Director Peter C. Farrell sold 20,000 shares of the business’s stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $77.01, for a total transaction of $1,540,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

ResMed Inc. (NYSE RMD) traded down 0.01% during midday trading on Friday, hitting $77.29. 78,293 shares of the stock traded hands. The stock has a market capitalization of $10.99 billion, a PE ratio of 32.20 and a beta of 0.77. The firm’s 50 day moving average is $77.03 and its 200-day moving average is $73.94. ResMed Inc. has a 12-month low of $56.59 and a 12-month high of $81.87.

ResMed (NYSE:RMD) last issued its quarterly earnings results on Tuesday, August 1st. The medical equipment provider reported $0.77 EPS for the quarter, topping the Zacks’ consensus estimate of $0.75 by $0.02. ResMed had a return on equity of 21.99% and a net margin of 16.56%. The company had revenue of $556.69 million for the quarter, compared to analysts’ expectations of $557.68 million. During the same quarter last year, the business earned $0.74 earnings per share. ResMed’s revenue was up 7.3% on a year-over-year basis. On average, analysts anticipate that ResMed Inc. will post $3.05 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Thursday, September 21st. Investors of record on Thursday, August 17th were given a $0.35 dividend. The ex-dividend date of this dividend was Tuesday, August 15th. This represents a $1.40 dividend on an annualized basis and a dividend yield of 1.81%. This is a boost from ResMed’s previous quarterly dividend of $0.33. ResMed’s dividend payout ratio (DPR) is presently 58.09%.

COPYRIGHT VIOLATION WARNING: This news story was reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/06/insider-selling-resmed-inc-rmd-director-sells-20000-shares-of-stock.html.

Institutional investors have recently added to or reduced their stakes in the business. YorkBridge Wealth Partners LLC grew its position in ResMed by 4.9% in the second quarter. YorkBridge Wealth Partners LLC now owns 1,476 shares of the medical equipment provider’s stock valued at $115,000 after acquiring an additional 69 shares during the last quarter. Creative Planning grew its position in ResMed by 97.1% in the second quarter. Creative Planning now owns 1,671 shares of the medical equipment provider’s stock valued at $130,000 after acquiring an additional 823 shares during the last quarter. Toronto Dominion Bank grew its position in ResMed by 12.8% in the second quarter. Toronto Dominion Bank now owns 1,740 shares of the medical equipment provider’s stock valued at $135,000 after acquiring an additional 197 shares during the last quarter. Van ECK Associates Corp grew its position in ResMed by 7.5% in the first quarter. Van ECK Associates Corp now owns 1,945 shares of the medical equipment provider’s stock valued at $140,000 after acquiring an additional 136 shares during the last quarter. Finally, Huntington National Bank bought a new position in ResMed in the second quarter valued at about $156,000. Hedge funds and other institutional investors own 60.10% of the company’s stock.

Several equities research analysts have issued reports on RMD shares. Bank of America Corporation lowered shares of ResMed from a “buy” rating to a “neutral” rating in a report on Wednesday, August 2nd. Credit Suisse Group AG lowered shares of ResMed from an “outperform” rating to a “neutral” rating in a report on Tuesday, August 8th. BidaskClub lowered shares of ResMed from a “strong-buy” rating to a “buy” rating in a report on Monday, July 24th. Barclays PLC boosted their price target on shares of ResMed from $65.00 to $68.00 and gave the company an “underweight” rating in a report on Monday, September 25th. Finally, BMO Capital Markets boosted their price target on shares of ResMed from $61.00 to $70.00 and gave the company a “market perform” rating in a report on Wednesday, August 2nd. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the stock. ResMed currently has an average rating of “Hold” and an average price target of $68.50.

ResMed Company Profile

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.